Key result
In patients over 60 years old surviving a transmural infarction, long-term oral anticoagulant therapy reduced mortality and recurrent myocardial infarction compared to placebo.
Why the study?
Does oral anticoagulant therapy reduce mortality and recurrent myocardial infarction in elderly patients who survived a transmural infarction?
RCT (n=738)
Does oral anticoagulant therapy reduce mortality and recurrent myocardial infarction in elderly patients who survived a transmural infarction?
Long-term oral anticoagulation significantly reduces mortality and recurrent myocardial infarction in elderly survivors of transmural infarction.
Answers are grounded in this paper and cite their sources.
May support long-term anticoagulation in elderly transmural MI survivors; leaves open confirmation in contemporary trials.
Evidence in favour of oral anticoagulant therapy (OAT) in patients suffering from an acute myocardial infarction has been published in 1977 by Chalmers and co-workers (New Engl. J. Med. 297, 1091). For OAT after discharge an International Review Group (IRG) concluded in 1970 that "anticoagulant therapy probably prolongs survival at least over two years, but that benefit is as a rule restricted to patients with a history of angina or previous infarction" (The Lancet, 1, 203). Since the IRG finished their analysis, favourable results of four additional comparative studies have been published, three of which were double-blind and performed in the Netherlands. These four studies demonstrated a beneficial effect of adequate oral anticoagulation. The latest study was performed to assess benefits and untoward reactions of long-term OAT in the elderly. Results were published in November 1980 (The Lancet, 2,989). Mortality in the 738 patients who entered the trial, all of whom older than sixty years, having survived a transmural infarction, and having been on OAT for at least six months (mean: six years), was lower in patients on active treatment (p = 0.016), due to the important difference in recurrent myocardial infarction (RMI). Fifty-eight RMI's occurred in the placebo group as compared to only twenty in the AC group (p less than 0.01). Fatal cerebrovascular accidents were evenly distributed over the two groups, with a preponderance of haemorrhage in patients on active treatment. No fatal extracranial haemorrhage occurred. Incidence and severity of bleeding complications were in agreement with good patient compliance. No significant relationship was found between the recurrence of infarction and either the age of the patient or the length of treatment before entering trial. The steadiness of the widening gap between the mortality and RMI's observed in the two groups indicates that the efficacy of OAT persisted throughout the entire observation period of two years.
No takes yet. Share an insight, caveat, or question.
E.A. Loeliger (1981) conducted an RCT in Myocardial infarction (n=738). Oral anticoagulant therapy vs. Placebo was evaluated on Mortality (p=0.016). In patients over 60 years old surviving a transmural infarction, long-term oral anticoagulant therapy reduced mortality and recurrent myocardial infarction compared to placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: